Farmacologia degli isomeri della metanfetamina negli esseri umani
Informazioni dettagliate sugli isomeri della metanfetamina: prevalenza e farmacologia negli esseri umani
This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Double-blind crossover study design. Healthy volunteers will attend three study drug administration visits, at least 7 days apart, in which methamphetamine isomer pharmacology will be assessed following intravenous administration of (1) S-(+)-methamphetamine, (2) R(-)-methamphetamine, or (3) a (1:1) racemic mixture of R-(-)- and S-(+)-methamphetamine. The order of these interventions will be counterbalanced across participants. Serial blood samples will be drawn during each dosing visit and compared with concurrent dried blood spots from a finger stick, oral fluid collections, and pooled urine specimens.
Primary Objective
- Characterize the pharmacokinetics of acute S-(+)-methamphetamine administration.
- Characterize the pharmacokinetics of acute R-(-)-methamphetamine administration.
- Characterize the pharmacokinetics of acute racemic (1:1) R-(-)- and S-(+)-methamphetamine administration.
Secondary Objectives
- Assess for evidence of stereo-selective metabolic pathways.
- Assess for evidence of subjective, cognitive, or physiological effects from acute R-(-)-methamphetamine administration.
- Assess for evidence of more than additive effects when administering racemic methamphetamine.
Correlative Objectives
- Compare biological methamphetamine and metabolite concentrations in surveyed biological matrices (i.e., plasma, whole blood, oral fluid, dried capillary blood spots, and urine) over time.
- Compare cognitive and subjective effects of acute S-(+)-methamphetamine, R-(-)-methamphetamine, and racemic methamphetamine administration.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Heather Barkholtz, PhD
- Numero di telefono: 608-890-1967
- Email: hbarkholtz@wisc.edu
Luoghi di studio
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53705
- University of Wisconsin
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Good mental health as determined by self-reported responses to the Psychopathology Screener
- Absence of any major cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal, or hepatic disease as determined by self-reported responses to the Medical History Screener
- English-speaking (able to provide consent and complete questionnaires)
- Written Informed Consent
Exclusion Criteria:
- Any serious prior adverse response to sympathomimetic agents or amphetamine analogs
- History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener
- Pregnancy or lactation (pregnancy test, if needed)
- Use of medications that may impact cognition or metabolism (e.g., mood stabilizers, sedatives)
- Dependent on prohibited concomitant therapy that cannot be withheld for 48 hours prior to and during study visits.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: S-Meth, R-Meth, Racemic Isomer
First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine |
15 mg
Altri nomi:
15 mg
Altri nomi:
15 mg R-Meth + 15 mg S-Meth |
|
Sperimentale: R-Meth, Racemic Isomer, S-Meth
First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth |
15 mg
Altri nomi:
15 mg
Altri nomi:
15 mg R-Meth + 15 mg S-Meth |
|
Sperimentale: Racemic Isomer, S-Meth, R-Meth
First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth |
15 mg
Altri nomi:
15 mg
Altri nomi:
15 mg R-Meth + 15 mg S-Meth |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Peak concentration (Cmax)
Lasso di tempo: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study. |
pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
|
Area under the concentration versus time curve (AUC)
Lasso di tempo: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
The pharmacokinetic analysis relies on observed drug and metabolite concentration measurements over time and across biological matrices (plasma, whole blood, dried capillary spots, oral fluid, urine) included in this study. |
pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cognitive Effects: Divided Attention Task (DAT)
Lasso di tempo: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
The DAT requires participants track a moving stimulus on a computer screen while simultaneously monitoring numbers located in the corners of the screen. Participants must respond to target numbers as they appear, and the task quantifies mean distance of the mouse cursor from the center of the target stimulus. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Cognitive Effects: Digital Symbol Substitution Task (DSST)
Lasso di tempo: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
The DSST asks participants to recreate patterns of various shapes presented on a computer screen using the keyboard. The total number of correct patterns are recorded within 90 seconds. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Cognitive Effects: Paced Serial Addition Task (PASAT)
Lasso di tempo: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
The PASAT has participants view a string of single-digit numbers and calculate the sum of the two most recently presented numbers. The total number of correct trials out of 90 will be recorded. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Subjective Effects: Drug Effect Questionnaire (DEQ)
Lasso di tempo: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
Subjective current general effects will be measured by asking the participant to rate if they feel the drug effect, if they like/dislike the drug effect, if they feel high, and if they would like more of the drug. Effects will be measured on a scale from "not at all" anchored at 0 to "extremely" at 100. |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
|
Subjective Effects: Number of Participants Who Answer 'True' for Amphetamine-specific questions
Lasso di tempo: Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
Participants will be asked 11 amphetamine-specific questions including feelings of pleasantness, excitability, memory, emptiness, body tingling, weird feeling, patience, and mental sharpness. Results are measured as either "true" (experiencing the specific state) or "false" (not experiencing the specific state). Number of participants who answered 'True' is reported here |
Visit 1 (baseline), Visit 2 (week 1), Visit 3 (week 2)
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Heather K Barkholtz, PhD, University of Wisconsin, Madison
- Investigatore principale: David Leinweber, MD, University of Wisconsin, Madison
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2024-1164
- A523000 (Altro identificatore: UW Madison)
- Protocol Version 2/12/25 (Altro identificatore: UW Madison)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .